MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, et al.